死亡飞车

China reports 522,000 new COVID-19 cases, one death in July amid fluctuating upward trend_我的网站

一 |     

    Photo： VCG
China reported 522,000 newly confirmed COVID-19 cases in July, including 487 severe cases and one related death with cases showing a fluctuating upward trend, China's national disease control authority said. 
The current uptick in infections represents another regular cyclical wave, with its severity comparable to surges seen in the past two years. The upward growth curve has slowed markedly, and the country is now on the plateau phase of this epidemic peak, said the Chinese Center for Disease Control and Prevention (Chinese CDC) on Thursday. 
All tested infection samples were confirmed to be the Omicron variant, with the NB.1.8.1 strain and its sublineages accounting for the majority of circulating cases, the Chinese CDC said. 
A Beijing-based respiratory disease specialist told the Global Times that waning population immunity, continued virus mutations that weaken existing antibody protection, and increased summer travel have contributed to the recent modest rise in infections. However, there is no evidence that the virus has become more pathogenic. Nationwide infections appear to be nearing their peak and case numbers may begin falling in late August. 
    A screenshot from Chinese CDC report on new COVID-19 cases in July nationwide
According to sentinel hospital surveillance data, from June 29-July 5 to July 27-August 2, the proportion of influenza-like illness among all outpatient and emergency visits at China's 1,041 COVID-19 and influenza sentinel hospitals edged up with slight fluctuations, standing at 4.3 percent, 4.4 percent, 4.5 percent, 4.4 percent and 4.5 percent, respectively.
During the same period, the COVID-19 positivity rate among patients with influenza-like illness in outpatient and emergency departments rose for consecutive weeks.
Several factors drove the fluctuating rise in COVID-19 cases in July. Population immunity has waned, as more than six months have passed since the last major wave of infections for most people, while continued SARS-CoV-2 mutations have reduced the protection provided by existing antibodies, Li Tongzeng, a respiratory disease medic from Beijing You An Hospital to the Capital Medical University, told the Global Times on Friday. 
These factors, combined with increased travel and population mobility during the summer vacation, contributed to the recent small-scale surge. Based on patterns observed in recent years, COVID-19 infections tend to rise every six to eight months as population immunity declines, said Li.
The expert noted that while the virus continues to mutate, there is no evidence that it has become more pathogenic. Clinical data show that most patients develop only mild symptoms, with very few progressing to pneumonia or requiring hospitalization.
The Chinese CDC noted on Thursday that since COVID-19 was reclassified as a Category B infectious disease under Category B management, it has evolved into a prevalent, recurring respiratory infectious disease in China, with one to two epidemic fluctuations occurring nationwide each year.
Li also noted that residual immunity from previous infections also helps reduce disease severity, with most reinfections presenting as mild upper respiratory symptoms that resolve within about a week. The single COVID-related death reported nationwide in July further indicates that the current fatality rate remains very low.
Judging from historical epidemic patterns and current case growth trajectories, national infection figures may begin to decline in late August. Nationwide case numbers are now nearly at their peak, with declines already observed in some regions, said Li. 
The Chinese CDC also said on Thursday that surveillance had not detected any variants posing major public health risks, nor had the current wave caused notable disruptions to the healthcare system.
The public is advised to take appropriate protective measures, including wearing masks when necessary, maintaining good personal hygiene, adopting healthy lifestyles and getting vaccinated as recommended.
。

二 |     以深之名，为深而战以赛代练，酣战练兵 “2026职业男子篮球挑战赛”2026职业男子篮球挑战赛重磅来袭万众瞩目的广东德比即将打响深圳马可波罗将与广东宏远在广东肇庆和惠州进行两场较量作为CBA联赛最具热度和看点的经典德比战，深圳马可波罗与广东宏远的每一次交锋，都是实力与底蕴的碰撞。两队皆是CBA季后赛常客，上赛季深圳马可波罗强势突围，斩获队史最佳战绩第三名；广东宏远则稳居联赛前五，底蕴深厚。

三 | 双雄集结，强强对垒，必将为广大球迷呈现一场精彩的篮球盛宴。为深而战肇庆站观赛指南⏰9月4日 20:00深圳马可波罗队 VS 广东宏远队购票购票渠道：大麦APP、大麦小程序比赛地点肇庆新区体育中心体育馆肇庆等你惠州站观赛指南⏰9月6日 20:00深圳马可波罗队 VS 广东宏远队购票比赛地点惠州体育馆C馆惠州等你每一场比赛都因你们的呐喊而滚烫球队周边。

Current article:http://uk4h29k.kenouguanruilianshanxiangshu.cfd/v8gxzs2/20260826/559327.html

Published on:14:37:10